August 12, 2019 07:03 AM EDTUpdated August 13, 04:42 AM
Financing

A top an­a­lyst spot­lights a wave of biotech star­tups look­ing to cat­a­pult on­to Nas­daq — or get bought out

John Carroll

Editor & Founder

There should be no short­age of biotech com­pa­nies look­ing to file an IPO — or ex­e­cute a buy­out deal — in 2020 and 2021.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da strikes $500M+ deal for Cal­i­for­nia biotech's ALS pro­gram

FDA picks apart Brain­Stor­m's po­ten­tial ALS treat­ment ahead of Wednes­day ad­comm

Ab­b­Vie ful­ly ditch­es I-Mab's CD47 drug af­ter ini­tial 2022 pull­back from $1B+ bet

No­vo signs up for near­ly a dozen car­diometa­bol­ic pro­grams out of Va­lo Health

For decades, can­cer drug de­vel­op­ers have fo­cused on in­hi­bi­tion. Now, a GV-backed start­up is eye­ing ac­ti­va­tion

sponsored

Da­ta Qual­i­ty 2.0: The Fu­ture of Re­al-World Ev­i­dence

A service from the Financial Times